Protagonist Therapeutics Inc (NASDAQ:PTGX) does about 742.64K shares in volume on a normal day but saw 731774 shares change hands in Tuesday trading. The company now has a market cap of 1.63B USD. Its current market price is $27.99, marking a decrease of -1.03% compared to the previous close of $28.28. The 52 week high reached by this stock is $33.34 whilst the lowest price level in 52 weeks is $13.72.
Protagonist Therapeutics Inc (PTGX) has a 20-day trading average at $29.15 and the current price is -16.05% off the 52-week high compared with 104.01% distance from its 52-week low. The 50-day simple moving average of the closing price is $28.05 and its 200-day simple moving average is $21.73. If we look at the stock’s price movements over the week, volatility stands at 3.19%, which increases to 3.75% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 45.53 to suggest the stock is neutral.
The consensus objective for the share price is $43.00, suggesting that the stock has a potential upside of 34.91% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 30, 2023 when CapitalOne initiated the stock to “Overweight” and issued a price target of $32. JMP Securities initiated its price target at $21.
Protagonist Therapeutics Inc (PTGX) stock is up 0.36% over the week and -12.94% over the past month. Its price is 22.07% year-to-date and 24.46% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of $0.44 above consensus estimates by $0.47. PTGX’s earnings per share are forecast to grow by 154.00% this year and -208.00% over next year. Expected sales for next quarter are $60 million, which analysts say will come at $152.5 million for the current fiscal year and next year at $137.5 million. In addition, estimates put the company’s current quarterly revenue at an average of $120 million.
To reach the target analysts have set, the stock logically needs to grow 34.91 percent from here.
Outstanding shares total 57.71M with insiders holding 1.75% of the shares and institutional holders owning 100.45% of the company’s common stock. The company has a return on investment of -23.45% and return on equity of -28.59%. The beta has a value of 2.06. Price to book ratio is 4.80 and price to sales ratio is 27.18.
